Omnicell Inc. (OMCL) Downgraded by Sidoti
Omnicell Inc. (NASDAQ:OMCL) was downgraded by analysts at Sidoti from a “buy” rating to a “neutral” rating in a research report issued on Thursday, The Fly reports.
A number of other analysts have also recently weighed in on OMCL. Zacks Investment Research cut Omnicell from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 3rd. FBR & Co raised their price target on Omnicell from $40.00 to $41.00 and gave the company an “outperform” rating in a research note on Friday, July 29th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $36.71.
Several institutional investors recently added to or reduced their stakes in OMCL. Diversified Trust Co bought a new position in Omnicell during the second quarter worth about $216,000. Legal & General Group Plc raised its position in Omnicell by 6.9% in the first quarter. Legal & General Group Plc now owns 8,829 shares of the company’s stock worth $244,000 after buying an additional 568 shares in the last quarter. Eqis Capital Management Inc. raised its position in Omnicell by 11.9% in the second quarter. Eqis Capital Management Inc. now owns 9,163 shares of the company’s stock worth $314,000 after buying an additional 971 shares in the last quarter. Bank of Montreal Can bought a new position in Omnicell during the second quarter worth about $322,000. Finally, Menta Capital LLC bought a new position in Omnicell during the first quarter worth about $332,000. 95.37% of the stock is currently owned by hedge funds and other institutional investors.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/08/omnicell-inc-omcl-downgraded-by-sidoti.html
In related news, EVP Robin Gene Seim sold 5,302 shares of the firm’s stock in a transaction dated Wednesday, July 6th. The stock was sold at an average price of $34.75, for a total transaction of $184,244.50. Following the transaction, the executive vice president now owns 55,420 shares of the company’s stock, valued at $1,925,845. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Gary S. Petersmeyer sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, September 6th. The stock was sold at an average price of $39.02, for a total value of $78,040.00. Following the transaction, the director now directly owns 19,987 shares in the company, valued at approximately $779,892.74. The disclosure for this sale can be found here. Corporate insiders own 3.75% of the company’s stock.
Shares of Omnicell (NASDAQ:OMCL) traded down 2.08% during trading on Thursday, hitting $39.56. The stock had a trading volume of 116,007 shares. The stock’s 50-day moving average is $37.47 and its 200-day moving average is $32.38. The stock has a market cap of $1.43 billion and a price-to-earnings ratio of 100.41. Omnicell has a 12-month low of $25.06 and a 12-month high of $40.50.
Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, July 28th. The company reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.06. The company earned $175.60 million during the quarter, compared to analyst estimates of $170.89 million. During the same quarter in the previous year, the business posted $0.28 earnings per share. The firm’s revenue was up 55.7% on a year-over-year basis. On average, equities research analysts expect that Omnicell will post $1.58 EPS for the current year.
Omnicell, Inc (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company operates through two operating segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Omnicell Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.